Latest Aortic valve stenosis Stories
NATICK, Mass., Jan. 4, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of Sadra Medical, Inc. of Los Gatos, California. The transaction follows the definitive merger agreement announced on November 19, 2010.
MOUNTAIN VIEW, Calif., Dec. 21 2010 /PRNewswire/ -- El Camino Hospital today announced its first patient implant in the Medtronic CoreValveÂ® U.S. Clinical Trial. El Camino Hospital is one of the first of 40 hospitals across the U.S.
NATICK, Mass. and LOS GATOS, Calif., Nov. 19, 2010 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the signing of a definitive merger agreement, under which Boston Scientific will acquire Sadra Medical, Inc., a development-stage company in Los Gatos, California.
Despite the promising results of the "Placement of Aortic Transcatheter Valves (PARTNER) trial," featured in the Oct. 21 issue of the New England Journal of Medicine, a cardiothoracic surgeon from Boston Medical Center (BMC) believes that surgical aortic-valve replacement should remain the standard treatment of aortic stenosis.
One-year data from the PARTNER clinical trial, published today in the New England Journal of Medicine, demonstrate that transcatheter aortic-valve implantation, compared with standard therapy, resulted in significantly lower rates of death among patients who cannot undergo surgery for aortic stenosis.
Implantation of a new bioprosthetic-tissue valve into the hearts of patients who have severe aortic stenosis and are too sick or too old for open-heart surgery has been found to both save lives and improve the quality of those lives.
Heart enlargement caused by narrowed aortic valves regresses faster in elderly women than in men after aortic valve replacement.
A new study shows that people with a common heart defect may also be more likely to have brain aneurysms.
- totally perplexed and mixed up.